• About us
• Contact

Advertisement

Organisation › Details

Genmab A/S (CSE: GEN, Nasdaq: GMAB)

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base includes a number of proprietary next generation antibody technologies Genmab has alliances with other leading pharmaceutical and biotechnology companies. *

 

	Start	1999-01-01 established
	Group	Genmab (Group)
	Industry	DuoBody technology platform (bispecific antibodies)
	Industry 2	Darzalex®
	Person	van de Winkel, Jan (Genmab 201106 CEO before CSO + Co-Founder before Medarex Europe)
	Person 2	Pagano, Anthony (Genmab 202003– CFO before SVP Finance + CorpDev since 2011 joined 2007)
	Region	København (Copenhagen)
	Country	Denmark
	Street	30 Carl Jacobsens Vej
	City	2500 Valby
		Address record changed: 2024-04-03
Basic data	Employees	D: 101 to 500 (2018-12-31)
	Currency	DKK
	Annual sales	3,040,539,000 (revenue, consolidated (2018) 2018-12-31)
	Profit	1,472,141,000 (2018-12-31)
	Cash	478,190,000 (2018-12-31)
		* Document for »About Section«: Genmab A/S. (7/12/19). "Press Release: Genmab and Blink Biomedical Enter into Commercial License Agreement". Copenhagen.
		Record changed: 2025-03-16

Advertisement

More documents for Genmab (Group)

• [1] Genmab A/S. (4/3/24). "Press Release: Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio". Copenhagen & Seattle, WA....
• [2] Argenx SE. (4/17/23). "Press Release: Argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology". Amsterdam....
• [3] BioNTech SE. (8/5/22). "Press Release: BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates". Mainz & Copenhagen....
• [4] Synaffix B.V.. (7/22/21). "Press Release: Synaffix Announces Deal with ProfoundBio Worth up to $246 Million Providing Access to Multiple Novel Linker-Payload Technologies". Amsterdam....
• [5] Genmab A/S. (11/24/20). "Press Release: Genmab Announces Enapotamab Vedotin Update. Genmab Will Not Advance the Development of Enapotamab Vedotin". Copenhagen....
• [6] Genmab A/S. (6/10/20). "Press Release: Genmab and AbbVie Announce Broad Oncology Collaboration". Copenhagen & North Chicago, IL....
• [7] Bioqube Ventures. (6/10/20). "Press Release: Bioqube Ventures Launches Bioqube Factory Fund I". Hasselt/Brussels....
• [8] Rentschler Biopharma SE. (5/27/20). "Press Release: Rentschler Biopharma Extends Collaboration with Genmab to U.S. Facility". Laupheim & Milford, MA....
• [9] CureVac AG. (3/11/20). "Press Release: Company Founder Ingmar Hoerr Succeeds Daniel Menichella as CEO of CureVac AG". Tübingen & Boston, MA....
• [10] Genmab A/S. (12/19/19). "Press Release: Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics". Copenhagen & Tübingen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.